GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaSGP Holding SE (XTER:PSG) » Definitions » Piotroski F-Score

PharmaSGP Holding SE (XTER:PSG) Piotroski F-Score : 8 (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PharmaSGP Holding SE Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PharmaSGP Holding SE has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for PharmaSGP Holding SE's Piotroski F-Score or its related term are showing as below:

XTER:PSG' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 9
Current: 8

During the past 5 years, the highest Piotroski F-Score of PharmaSGP Holding SE was 9. The lowest was 4. And the median was 7.


PharmaSGP Holding SE Piotroski F-Score Historical Data

The historical data trend for PharmaSGP Holding SE's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaSGP Holding SE Piotroski F-Score Chart

PharmaSGP Holding SE Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 7.00 4.00 9.00

PharmaSGP Holding SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 9.00 8.00 8.00 8.00

Competitive Comparison of PharmaSGP Holding SE's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaSGP Holding SE's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaSGP Holding SE's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaSGP Holding SE's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PharmaSGP Holding SE's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 4.749 + 4.559 + 4.118 + 5.373 = €18.8 Mil.
Cash Flow from Operations was 9.227 + 6.921 + -0.886 + 14.878 = €30.1 Mil.
Revenue was 25.424 + 30.205 + 28.162 + 30.209 = €114.0 Mil.
Gross Profit was 22.961 + 27.657 + 25.547 + 27.502 = €103.7 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(131.494 + 131.299 + 140.929 + 134.154 + 129.516) / 5 = €133.4784 Mil.
Total Assets at the begining of this year (Sep23) was €131.5 Mil.
Long-Term Debt & Capital Lease Obligation was €0.1 Mil.
Total Current Assets was €67.5 Mil.
Total Current Liabilities was €29.8 Mil.
Net Income was 3.343 + 2.845 + 4.017 + 4.786 = €15.0 Mil.

Revenue was 21.878 + 24.011 + 25.698 + 25.966 = €97.6 Mil.
Gross Profit was 19.721 + 21.736 + 23.323 + 23.617 = €88.4 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(125.503 + 129.109 + 133.559 + 132.794 + 131.494) / 5 = €130.4918 Mil.
Total Assets at the begining of last year (Sep22) was €125.5 Mil.
Long-Term Debt & Capital Lease Obligation was €0.6 Mil.
Total Current Assets was €60.5 Mil.
Total Current Liabilities was €23.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PharmaSGP Holding SE's current Net Income (TTM) was 18.8. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PharmaSGP Holding SE's current Cash Flow from Operations (TTM) was 30.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=18.799/131.494
=0.1429647

ROA (Last Year)=Net Income/Total Assets (Sep22)
=14.991/125.503
=0.11944734

PharmaSGP Holding SE's return on assets of this year was 0.1429647. PharmaSGP Holding SE's return on assets of last year was 0.11944734. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PharmaSGP Holding SE's current Net Income (TTM) was 18.8. PharmaSGP Holding SE's current Cash Flow from Operations (TTM) was 30.1. ==> 30.1 > 18.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0.125/133.4784
=0.00093648

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0.563/130.4918
=0.00431445

PharmaSGP Holding SE's gearing of this year was 0.00093648. PharmaSGP Holding SE's gearing of last year was 0.00431445. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=67.452/29.782
=2.26485797

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=60.544/23.665
=2.55837735

PharmaSGP Holding SE's current ratio of this year was 2.26485797. PharmaSGP Holding SE's current ratio of last year was 2.55837735. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PharmaSGP Holding SE's number of shares in issue this year was 11.923. PharmaSGP Holding SE's number of shares in issue last year was 11.948. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=103.667/114
=0.90935965

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=88.397/97.553
=0.90614333

PharmaSGP Holding SE's gross margin of this year was 0.90935965. PharmaSGP Holding SE's gross margin of last year was 0.90614333. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=114/131.494
=0.86695971

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=97.553/125.503
=0.77729616

PharmaSGP Holding SE's asset turnover of this year was 0.86695971. PharmaSGP Holding SE's asset turnover of last year was 0.77729616. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PharmaSGP Holding SE has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

PharmaSGP Holding SE  (XTER:PSG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PharmaSGP Holding SE Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of PharmaSGP Holding SE's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaSGP Holding SE Business Description

Traded in Other Exchanges
Address
Lochhamer Schlag 1, Graefelfing, Munich, DEU, 82166
PharmaSGP Holding SE is a pharmaceutical company. The company develops chemical-free, over-the-counter (OTC) drugs and healthcare products. The product portfolio includes RUBAXX for rheumatic pain Restaxil for nerve pain, and Deseo for sexual dysfunction. It has established various consumer brands in important indication areas, such as rheumatic and neuralgic pain or sexual weakness Also, the company offers products for skin aging and vertigo.
Executives
Dr. Clemens Fischer Supervisory Board
Madlena Hohlefelder Supervisory Board

PharmaSGP Holding SE Headlines

No Headlines